Guy Lagaud

2.2k total citations · 1 hit paper
16 papers, 1.7k citations indexed

About

Guy Lagaud is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Surgery. According to data from OpenAlex, Guy Lagaud has authored 16 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 5 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Guy Lagaud's work include Neuropeptides and Animal Physiology (5 papers), Nitric Oxide and Endothelin Effects (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Guy Lagaud is often cited by papers focused on Neuropeptides and Animal Physiology (5 papers), Nitric Oxide and Endothelin Effects (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Guy Lagaud collaborates with scholars based in United States, Canada and France. Guy Lagaud's co-authors include George J. Christ, Michael P. Lisanti, Harry Hou, Jeffery A. Engelman, Winfried Edelmann, Burkhard Kneitz, Babak Razani, Xiao Lan Zhang, Xiaobo Wang and Robert G. Russell and has published in prestigious journals such as Journal of Biological Chemistry, Molecular and Cellular Biology and The Journal of Physiology.

In The Last Decade

Guy Lagaud

16 papers receiving 1.7k citations

Hit Papers

Caveolin-1 Null Mice Are Viable but Show Evidence of Hype... 2001 2026 2009 2017 2001 250 500 750

Peers

Guy Lagaud
Grzegorz Sowa United States
Jeffrey B. Michel United States
Kenneth Song United States
Scott L. Schissel United States
Angela Wirth Germany
Ronald Kahn United States
Grzegorz Sowa United States
Guy Lagaud
Citations per year, relative to Guy Lagaud Guy Lagaud (= 1×) peers Grzegorz Sowa

Countries citing papers authored by Guy Lagaud

Since Specialization
Citations

This map shows the geographic impact of Guy Lagaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Lagaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Lagaud more than expected).

Fields of papers citing papers by Guy Lagaud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Lagaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Lagaud. The network helps show where Guy Lagaud may publish in the future.

Co-authorship network of co-authors of Guy Lagaud

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Lagaud. A scholar is included among the top collaborators of Guy Lagaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Lagaud. Guy Lagaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Arnold, Michael, Aleksey I. Gerasyuto, Jiashi Wang, et al.. (2017). 4-Hydroxy-2-pyridones: Discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis. Bioorganic & Medicinal Chemistry Letters. 27(22). 5014–5021. 9 indexed citations
2.
Lagaud, Guy, et al.. (2012). The cholecystokinin CCK2 receptor antagonist, JNJ‐26070109, inhibits gastric acid secretion and prevents omeprazole‐induced acid rebound in the rat. British Journal of Pharmacology. 166(5). 1684–1693. 15 indexed citations
3.
Morton, Magda F., Terrance D. Barrett, Jamie Freedman, et al.. (2011). JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability. Journal of Pharmacology and Experimental Therapeutics. 338(1). 328–336. 5 indexed citations
4.
Venkatesan, Hariharan, Wen Yan, Terrance D. Barrett, et al.. (2009). Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy. Bioorganic & Medicinal Chemistry Letters. 19(22). 6376–6378. 13 indexed citations
5.
Barrett, Terrance D., et al.. (2008). Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction. British Journal of Pharmacology. 153(8). 1650–1658. 10 indexed citations
6.
Morton, Magda F., Terrance D. Barrett, Wen Yan, et al.. (2007). 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1 H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a Novel, Potent, and Selective Cholecystokinin 1 Receptor Antagonist: In Vitro and in Vivo Pharmacological Comparison with Dexloxiglumide. Journal of Pharmacology and Experimental Therapeutics. 323(2). 562–569. 6 indexed citations
7.
Woodman, Scott E., Michelle W.-C. Cheung, Amanda North, et al.. (2004). Urogenital Alterations in Aged Male Caveolin-1 Knockout Mice. The Journal of Urology. 171(2). 950–957. 64 indexed citations
8.
Razani, Babak, Xiaobo Wang, Jeffery A. Engelman, et al.. (2002). Caveolin-2-Deficient Mice Show Evidence of Severe Pulmonary Dysfunction without Disruption of Caveolae. Molecular and Cellular Biology. 22(7). 2329–2344. 263 indexed citations
9.
Lagaud, Guy, Nathalie Gaudreault, Edwin D.W. Moore, C. van Breemen, & Ismail Laher. (2002). Pressure-dependent myogenic constriction of cerebral arteries occurs independently of voltage-dependent activation. American Journal of Physiology-Heart and Circulatory Physiology. 283(6). H2187–H2195. 77 indexed citations
10.
Lagaud, Guy, K Venkateswarlu, Harm J. Knot, George J. Christ, & Ismail Laher. (2002). Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries. American Journal of Physiology-Heart and Circulatory Physiology. 283(6). H2177–H2186. 43 indexed citations
11.
Lagaud, Guy, Esther Masih‐Khan, Kai Song, C. van Breemen, & Gregory P. Dubé. (2001). Influence of Type II Diabetes on Arterial Tone and Endothelial Function in Murine Mesenteric Resistance Arteries. Journal of Vascular Research. 38(6). 578–589. 92 indexed citations
12.
Razani, Babak, Jeffery A. Engelman, Xiaobo Wang, et al.. (2001). Caveolin-1 Null Mice Are Viable but Show Evidence of Hyperproliferative and Vascular Abnormalities. Journal of Biological Chemistry. 276(41). 38121–38138. 975 indexed citations breakdown →
13.
Breemen, C. van, et al.. (1999). A Link between Vasomotion and Spontaneous Oscillations of Oxygen in Rat Brain. Advances in experimental medicine and biology. 471. 111–116. 4 indexed citations
14.
Lagaud, Guy, et al.. (1999). Nonspecific Inhibition of Myogenic Tone by PD98059, a MEK1 Inhibitor, in Rat Middle Cerebral Arteries. Biochemical and Biophysical Research Communications. 257(2). 523–527. 37 indexed citations
15.
Lagaud, Guy, J.C. Stoclet, & Ramaroson Andriantsitohaina. (1996). Calcium handling and purinoceptor subtypes involved in ATP‐induced contraction in rat small mesenteric arteries.. The Journal of Physiology. 492(3). 689–703. 40 indexed citations
16.
Andriantsitohaina, Ramaroson, et al.. (1995). Effects of cGMP on calcium handling in ATP-stimulated rat resistance arteries. American Journal of Physiology-Heart and Circulatory Physiology. 268(3). H1223–H1231. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026